Your session is about to expire
← Back to Search
Phase 1: Dose confirmation of AB-101 plus Rituximab combination for Lupus Nephritis
Study Summary
This trial is testing a new cell product called AB-101, which contains natural killer cells that can enhance the effect of antibody therapies. The trial will enroll adults with lupus nephritis who have not
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current capacity for patient enrollment in this clinical trial?
"Affirmative, the details on clinicaltrials.gov specify that this investigation is presently seeking suitable participants. The trial was initially disclosed on February 24th, 2024, and its most recent update occurred on February 15th, 2024. Recruitment aims to enroll a total of 18 patients from a single designated site."
Are medical researchers actively seeking participants for this clinical trial?
"Yes, the details on clinicaltrials.gov indicate that this trial is currently enrolling participants. The trial was first listed on February 24th, 2024 and was last revised on February 15th, 2024. A total of 18 individuals are sought for participation from a single site."
Are individuals older than thirty years being considered for enrollment in this research investigation?
"Individuals aged 18 to 99 are eligible for participation in this research, as outlined in the inclusion criteria."
What are the risks associated with Phase 1: Dose Verification of AB-101 when used as a standalone treatment for individuals?
"The safety evaluation for Phase 1: Dose verification of AB-101 as a standalone treatment is rated at level 1 by our team due to the preliminary nature of this trial, which has limited evidence supporting both safety and effectiveness."
Share this study with friends
Copy Link
Messenger